GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anatara Lifesciences Ltd (ASX:ANR) » Definitions » EV-to-EBIT

Anatara Lifesciences (ASX:ANR) EV-to-EBIT : -3.24 (As of May. 13, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Anatara Lifesciences EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Anatara Lifesciences's Enterprise Value is A$6.55 Mil. Anatara Lifesciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$-2.02 Mil. Therefore, Anatara Lifesciences's EV-to-EBIT for today is -3.24.

The historical rank and industry rank for Anatara Lifesciences's EV-to-EBIT or its related term are showing as below:

ASX:ANR' s EV-to-EBIT Range Over the Past 10 Years
Min: -42.3   Med: -1.11   Max: 1.12
Current: -3.24

During the past 9 years, the highest EV-to-EBIT of Anatara Lifesciences was 1.12. The lowest was -42.30. And the median was -1.11.

ASX:ANR's EV-to-EBIT is ranked worse than
100% of 436 companies
in the Biotechnology industry
Industry Median: 9.28 vs ASX:ANR: -3.24

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Anatara Lifesciences's Enterprise Value for the quarter that ended in Dec. 2023 was A$2.61 Mil. Anatara Lifesciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$-2.02 Mil. Anatara Lifesciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -77.51%.


Anatara Lifesciences EV-to-EBIT Historical Data

The historical data trend for Anatara Lifesciences's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anatara Lifesciences EV-to-EBIT Chart

Anatara Lifesciences Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only -1.88 -0.90 -3.78 -1.12 -1.46

Anatara Lifesciences Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -1.12 - -1.46 -

Competitive Comparison of Anatara Lifesciences's EV-to-EBIT

For the Biotechnology subindustry, Anatara Lifesciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anatara Lifesciences's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anatara Lifesciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Anatara Lifesciences's EV-to-EBIT falls into.



Anatara Lifesciences EV-to-EBIT Calculation

Anatara Lifesciences's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=6.546/-2.022
=-3.24

Anatara Lifesciences's current Enterprise Value is A$6.55 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Anatara Lifesciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$-2.02 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Anatara Lifesciences  (ASX:ANR) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Anatara Lifesciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-2.022/2.608668
=-77.51 %

Anatara Lifesciences's Enterprise Value for the quarter that ended in Dec. 2023 was A$2.61 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Anatara Lifesciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$-2.02 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Anatara Lifesciences EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Anatara Lifesciences's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Anatara Lifesciences (ASX:ANR) Business Description

Traded in Other Exchanges
N/A
Address
c/- Perks, 81 Flinders Street, Level 8, Adelaide, SA, AUS, 5000
Anatara Lifesciences Ltd is developing non-antibiotic oral solutions for gastrointestinal diseases in animals and humans. Its products include the Gastrointestinal ReProgramming dietary supplement (GaRP) for humans and Detach for animals. It generates its income from license revenue.

Anatara Lifesciences (ASX:ANR) Headlines

No Headlines